论文部分内容阅读
巴德-吉亚利综合征（Budd-Chiari syndrome，B-CS）是由肝静脉流出道梗阻导致的复杂肝脏血管疾病。我国B-CS患者的发病特点及治疗方法与西方国家存在明显差异。鉴于我国B-CS的特点，中国研究型医院学会布-加综合征及肝脏血管病专业委员会组织国内本领域相关专家制定了《中国巴德-吉亚利综合征多学科协作诊治专家共识（2021版）》。本共识对国内B-CS的流行病学、发病原因、疾病分型、临床表现、诊断及治疗方法等研究现状进行逐一阐述，旨在为临床医师制定最佳的治疗方案提供指导，以进一步规范和提高国内B-CS的综合诊治水平及基础研究能力。“,”Budd-Chiari syndrome (B-CS) is a complicated hepatic vascular disease caused by hepatic venous outflow obstruction.There are significant differences in the pathogenesis and treatment of B-CS between China and Western countries.Given the characteristics of B-CS in our country,Budd-Chiari Syndrome and Hepatic Vascular Diseases Professional Committee of Chinese Research Hospital Association organizes domestic experts in this field to formulate the “Chinese multidisciplinary collaborative expert consensus for the diagnosis and treatment of Budd-Chiari syndrome（2021 version）”.This consensus elaborates the research status of epidemiology,pathogenesis,disease classification,clinical manifestations,diagnosis and treatment of B-CS in China.Conducting basic research on pathogenesis and clinical research with high level evidence are important work direction in the future.This consensus is expected to provide guidance for clinicians to make optimal therapeutic schedules,so as to further standardize and improve the comprehensive diagnosis and treatment and basic research level of B-CS in China.